SHANGHAI – It’s not often that Chinese biopharmas are able to nab China rights for a promising late-stage oncology candidate in global trials. But that’s exactly what Shanghai-based Zai Lab Ltd. did when it obtained exclusive China rights for niraparib from Tesaro Inc., of Waltham, Mass. A PARP inhibitor, niraparib has shown promise in phase III ovarian cancer trials and is being evaluated in BRCA-mutant breast cancer and prostate cancer.